156 related articles for article (PubMed ID: 25948779)
1. Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases.
Ali N; Chandrakesan P; Nguyen CB; Husain S; Gillaspy AF; Huycke M; Berry WL; May R; Qu D; Weygant N; Sureban SM; Bronze MS; Dhanasekaran DN; Houchen CW
Oncotarget; 2015 Aug; 6(24):20327-44. PubMed ID: 25948779
[TBL] [Abstract][Full Text] [Related]
2. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.
Sureban SM; Madhoun MF; May R; Qu D; Ali N; Fazili J; Weygant N; Chandrakesan P; Ding K; Lightfoot SA; Houchen CW
Oncotarget; 2015 Nov; 6(35):37200-15. PubMed ID: 26468984
[TBL] [Abstract][Full Text] [Related]
3. Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis.
Ito H; Tanaka S; Akiyama Y; Shimada S; Adikrisna R; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Yamaoka S; Tanabe M
PLoS One; 2016; 11(1):e0146564. PubMed ID: 26764906
[TBL] [Abstract][Full Text] [Related]
4. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
Weygant N; Qu D; Berry WL; May R; Chandrakesan P; Owen DB; Sureban SM; Ali N; Janknecht R; Houchen CW
Mol Cancer; 2014 May; 13():103. PubMed ID: 24885928
[TBL] [Abstract][Full Text] [Related]
5. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.
Liu Y; Ferguson FM; Li L; Kuljanin M; Mills CE; Subramanian K; Harshbarger W; Gondi S; Wang J; Sorger PK; Mancias JD; Gray NS; Westover KD
Cell Chem Biol; 2020 Oct; 27(10):1229-1240.e4. PubMed ID: 32755567
[TBL] [Abstract][Full Text] [Related]
6. Doublecortin-like kinase 1 is a therapeutic target in squamous cell carcinoma.
Standing D; Arnold L; Dandawate P; Ottemann B; Snyder V; Ponnurangam S; Sayed A; Subramaniam D; Srinivasan P; Choudhury S; New J; Kwatra D; Ramamoorthy P; Roy BC; Shadoin M; Al-Rajabi R; O'Neil M; Gunewardena S; Ashcraft J; Umar S; Weir SJ; Tawfik O; Padhye SB; Biersack B; Anant S; Thomas SM
Mol Carcinog; 2023 Feb; 62(2):145-159. PubMed ID: 36218231
[TBL] [Abstract][Full Text] [Related]
7. Repurposing diacerein to suppress colorectal cancer growth by inhibiting the DCLK1/STAT3 signaling pathway.
Ye Q; Zhu Y; Shi M; Lv L; Gong Y; Zhang L; Yang L; Zhao H; Zhao C; Xu H
Chin J Nat Med; 2024 Apr; 22(4):318-328. PubMed ID: 38658095
[TBL] [Abstract][Full Text] [Related]
8. Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
Dogra S; Elayapillai SP; Qu D; Pitts K; Filatenkov A; Houchen CW; Berry WL; Moxley K; Hannafon BN
Cancer Lett; 2023 Dec; 578():216437. PubMed ID: 37838282
[TBL] [Abstract][Full Text] [Related]
9. Autoregulatory control of microtubule binding in doublecortin-like kinase 1.
Agulto RL; Rogers MM; Tan TC; Ramkumar A; Downing AM; Bodin H; Castro J; Nowakowski DW; Ori-McKenney KM
Elife; 2021 Jul; 10():. PubMed ID: 34310279
[TBL] [Abstract][Full Text] [Related]
10. Doublecortin-like Kinase 1 Regulates α-Synuclein Levels and Toxicity.
Vázquez-Vélez GE; Gonzales KA; Revelli JP; Adamski CJ; Alavi Naini F; Bajić A; Craigen E; Richman R; Heman-Ackah SM; Wood MJA; Rousseaux MWC; Zoghbi HY
J Neurosci; 2020 Jan; 40(2):459-477. PubMed ID: 31748376
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells.
Moore LL; Houchen CW
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003596
[TBL] [Abstract][Full Text] [Related]
12. DCLK1 phosphorylates the microtubule-associated protein MAP7D1 to promote axon elongation in cortical neurons.
Koizumi H; Fujioka H; Togashi K; Thompson J; Yates JR; Gleeson JG; Emoto K
Dev Neurobiol; 2017 Apr; 77(4):493-510. PubMed ID: 27503845
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of doublecortin-like kinase 1 inhibitors and their bioactivity evaluation.
Pan P; Ji D; Li Z; Meng X
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2287990. PubMed ID: 38062554
[TBL] [Abstract][Full Text] [Related]
14. Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway.
Yang B; Zhao Y; Luo W; Zhu W; Jin L; Wang M; Ye L; Wang Y; Liang G
Cell Death Dis; 2023 Jul; 14(7):419. PubMed ID: 37443105
[TBL] [Abstract][Full Text] [Related]
15. Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma.
Broner EC; Trujillo JA; Korzinkin M; Subbannayya T; Agrawal N; Ozerov IV; Zhavoronkov A; Rooper L; Kotlov N; Shen L; Pearson AT; Rosenberg AJ; Savage PA; Mishra V; Chatterjee A; Sidransky D; Izumchenko E
Front Oncol; 2021; 11():677051. PubMed ID: 34336664
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a doublecortin-like kinase 1 inhibitor to prevent inflammatory responses in acute lung injury.
Cai B; Xu Y; Luo R; Lu K; Wang Y; Zheng L; Zhang Y; Yin L; Tu L; Luo W; Zheng L; Zhang F; Lv X; Tang Q; Liang G; Chen L
Bioorg Chem; 2024 Apr; 145():107215. PubMed ID: 38394920
[TBL] [Abstract][Full Text] [Related]
17. Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis.
Westphalen CB; Takemoto Y; Tanaka T; Macchini M; Jiang Z; Renz BW; Chen X; Ormanns S; Nagar K; Tailor Y; May R; Cho Y; Asfaha S; Worthley DL; Hayakawa Y; Urbanska AM; Quante M; Reichert M; Broyde J; Subramaniam PS; Remotti H; Su GH; Rustgi AK; Friedman RA; Honig B; Califano A; Houchen CW; Olive KP; Wang TC
Cell Stem Cell; 2016 Apr; 18(4):441-55. PubMed ID: 27058937
[TBL] [Abstract][Full Text] [Related]
18. DCLK1 is Overexpressed and Associated with Immune Cell Infiltration in Hepatocellular Carcinoma.
Velázquez-Enríquez JM; Cerna R; Beltrán-Ramírez O; Piña-Vázquez C; Villa-Treviño S; Vásquez-Garzón VR
Biochem Genet; 2024 Jan; ():. PubMed ID: 38294590
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pancreatic cancer.
Chen Y; Meng L; Wang W; Ye L; Huang L; Wang C; Wang S; Li M; Pei Y; Zhang S; Zou Y; Xu Y
Eur J Med Chem; 2023 Dec; 261():115846. PubMed ID: 37862816
[TBL] [Abstract][Full Text] [Related]
20. DCLK1 and its oncogenic functions: A promising therapeutic target for cancers.
Ye L; Liu B; Huang J; Zhao X; Wang Y; Xu Y; Wang S
Life Sci; 2024 Jan; 336():122294. PubMed ID: 38007147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
